Moreover, olaparib maintenance therapy brought substantial PFS benefits with a 70% lower risk of disease progression or death in patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation [114]. This evidence concerns the gene BRCA1 and ovarian cancer.